FOLH1 and prostate cancer: More recently, the 177Lu-labeled prostate-specific membrane antigen (PSMA) ligand 177Lu-PSMA-617 (Pluvicto; Advanced Accelerator Applications) has been approved for the treatment of PSMA-positive metastatic castration-resistant prostate cancer patients (2,3).